In the intestine ( Figure 6 ), the treatment in the IUGR-VEGF and IUGR-IGF groups showed a trend to increase both the number of crypts/mm 2 ( p = 0.183) and the number of villi/mm 2 when compared with the IUGR-CON group ( p = 0.089); however, both the IUGR-VEGF and IUGR-IGF groups showed a significantly shorter villous length and a trend toward a lower crypt depth than in the IUGR-CON group ( p = 0.045 and p = 0.147, respectively). 4.
Although the changes were not statistically significant, TgHD iPSCs showed a trend toward upregulation of hexokinase 2 ( HK2 ) ( P =0.1833) and glyceraldehyde 3-phosphate dehydrogenase ( GAPDH ) ( P =0.0555), and downregulation of pyruvate kinase ( PKM ) ( P =0.2180), relative to WT iPSCs, indicating early metabolic dysregulation in TgHD iPSCs.
Additionally, other cytokines showed a trend towards statistical significance, including another Th2 response cytokine, IL-4 ( p = 0.1837) ( Figure 2 D), TNF-α ( p = 0.0690) ( Figure 2 A), and IL-6 ( p = 0.0599) ( Figure 2 B).
Finally, dogs with CMCs expressing high levels of CD109 showed a trend toward decreased survival ( p = 0.1844) compared to dogs with CMCs expressing low levels of CD109 (Fig. 4F ).
With regard to body weight, patients with obesity—meaning a BMI of more than 30—showed a trend towards less compliance than patients with normal weight or overweight (20.23 ± 5.77 vs. 21.62 ± 4 h, p = 0.185).
The VFI showed a trend towards improvement, albeit without statistical significance in either group (enhanced: p = 0.186, standard: p = 0.813), while the magnitude of change also lacked significance ( p = 0.519).
For patients with mild COVID-19, all were alive and discharged (Figure 2 A-B), but CP showed a trend toward a longer disease duration than PWC (median, 33.0 vs. 25.0 days, p = 0.187, Figure 2 C), suggesting CP with mild COVID-19 tend to have a longer recovery period.
The last two ASOs, even though not significant, showed a trend for upregulation (ASO 08, p = .187; ASO 74, p = .092) (Fig. 3C and D, and Supplementary Table S2 ).
Accordingly, treated subjects were taking higher prednisone-equivalent doses at time of COVID-19 diagnosis [5 (0–10) mg/day] than untreated subjects [0 (0–2.5) mg/day; p = 0.002] and showed a trend towards a higher frequency of concomitant immunosuppressant treatment (67% vs. 48%; p = 0.187].
While poorly differentiated tumors showed a trend toward poorer survival (HR 2.00, 95% CI 0.73–5.03, p = 0.187), this association did not reach statistical significance.
HOMA-IR showed a trend for increased insulin resistance in both the HV ( P = 0.188) and HQ ( P = 0.06) HFD groups, with no effect of Q treatment ( Figure 2(g) ) but has not reached statistical significance due to variability.
Paradoxically, patients who developed nephrotoxicity showed a trend toward better survival outcomes: median PFS was 30 months versus 20 months ( p = 0.188), and the 3-year OS rate was 77.9% versus 63.8% ( p = 0.801), though these differences were not statistically significant.
Rs13278062 showed a trend towards an association with the same direction of effect (OR = 1.19, P = 0.189, Table 1 ).
The 2 variants, rs2279343 and rs2279344, showed a trend towards an association ( P = .19 and P = .11, respectively).
While data showed a trend towards higher NRM after MAC [21.4% (95% CI: 12.4-32.1%) vs. 13.1% (95% CI: 6.0-22.9%, P = 0.19], the cumulative incidence of relapse did not show a significant difference [29.3% (95% CI: 18.7–40.7%) vs. 39.2% (95% CI: 26.7-51.4%, P = 0.29] (Table 3 ).
PI-RADS also showed a trend for worse performance, but at a P value of P=0.19 also not significant.
As shown in Supplementary Figure S5 , patients receiving tafamidis showed a trend toward improved outcomes for the combined endpoint and the endpoint death/htx ( p = 0.19).
Median HR-CTV D 90 > 90 Gy 10 showed a trend toward improved local control (LC) ( p = 0.19).
Longer prehospital delay showed a trend toward higher mortality (adjusted OR 1.39, 95% CI 0.81–1.74; p = 0.19).
Asic2 −/− and Asic3 −/− mice showed no difference in disease progression as compared with wild-type littermates, although Asic2 −/− mice showed a trend to increased disease severity (F (1,20) = 1.778, P = 0.19) ( Fig. 1a ).
Evidence on compliance rate and the risk-reducing effect of aspirin showed a trend to lower incidence of preterm pre-eclampsia with an aspirin adherence ≥90% in comparison to <90% (OR=0.24 vs OR=0.65, p=0.19) 28 .
Twenty-eight patients with at least minimal response showed a trend toward lower detection rate of MYD88 L265P mutation (25.0% vs. 66.7%, P = 0.19) and mutant allele burden (median, 0.00% vs. 0.22%, P = 0.07), compared to 3 patients less than minimal response.
When soluble protein levels were analyzed as continuous variables using the Cox proportional hazards model, baseline VEGF-C was the only soluble protein significantly associated with TTP by univariate analysis (HR = 0.413; P = 0.0165) and showed a trend towards an association with OS (HR = 0.683; P = 0.190; Table 4 ). sVEGFR-2 ratio to baseline at cycle 1 day 28 was the only soluble protein significantly associated with OS (HR = 0.049; P = 0.0253).
Furthermore, when stratified by stage, primary OCs showed a trend in higher IL-10 levels with more advanced disease (412.8 pg/mL in advanced stages versus 328.7 pg/mL in early stages for serous OCs; p = 0.19; Figure 1 B).
No subgroup demonstrated a statistically significant association between CTI-WHtR and MACCE in the fully adjusted model, although the elderly subgroup (age ≥ 60 years) approached significance (HR 1.16, 95% CI 1.00–1.34, P = 0.053) and the overweight subgroup (BMI ≥ 24) showed a trend (HR 1.09, 95% CI 0.96–1.25, P = 0.19).